StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) stock

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302571% above fair value
$403.60−9.66 (-2.34%)

Close on Nov 18, 2026Market cap $45.89BP/E 72.2Yield –

Earnings

BeOne Medicines's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$1.90B
+35.7% on a year earlier
non-GAAP diluted Earnings per ADS, Q3 FY2026
$4.59
$2.65 a year earlier
Latest guidance
Raised
Nov 5, 2026 · 6 items

Quarterly results

Revenue and earnings per share from each of BeOne Medicines's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open$1.90B+35.7%$3.28$4.59Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026before the open$1.71B+29.6%$0.16$3.84Release
Q1 FY2026ended Mar 31, 2026May 6, 2026before the open$1.50B+36.4%$1.96$3.24Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$1.50B–$0.58$1.95Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open$1.40B+39.7%$1.09$2.65Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025before the open$1.32B+41.6%$0.84$2.25Release
Q1 FY2025ended Mar 31, 2025May 7, 2025before the open$1.10B+46.3%$0.01$1.22Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open––-$0.11–Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open$1.00B+28.2%––Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024before the open$929.00M+56.1%-$0.09–Release
Q1 FY2024ended Mar 31, 2024May 8, 2024before the open$752.00M+67.9%-$0.19–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

BeOne Medicines's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenueFY2026$6.90B – $7.00B$6.30B – $6.50BRaisedNov 5, 2026
Total revenueFY2026$6.20B – $6.40B–NewFeb 26, 2026
GAAP operating incomeGAAPFY2026$1.20B – $1.30B$750.00M – $850.00MRaisedNov 5, 2026
GAAP operating incomeGAAPFY2026$700.00M – $800.00M–NewFeb 26, 2026
non-GAAP operating incomenon-GAAPFY2026$1.90B – $2.00B$1.45B – $1.55BRaisedNov 5, 2026
Non-GAAP operating incomenon-GAAPFY2026$1.40B – $1.50B–NewFeb 26, 2026
Diluted ADS outstandingFY2026118118ReaffirmedNov 5, 2026
Diluted ADS outstandingFY2026118–NewAug 5, 2026
GAAP operating expensesGAAPFY2026$4.90B – $5.00B$4.70B – $4.90BRaisedNov 5, 2026
GAAP operating expenses (combined R&D and SG&A)GAAPFY2026$4.70B – $4.90B–NewFeb 26, 2026
Other income (expense)FY2026$25.00M – $50.00M$25.00M – $50.00MReaffirmedNov 5, 2026
Other income (expense)FY2026$25.00M – $50.00M–NewAug 5, 2026

Guidance vs results

The last range BeOne Medicines gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$5.10B – $5.30B$5.31BΣ4QAbove range

Guidance history

Every forecast BeOne Medicines put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026GAAP operating incomeFY2026$1.20B – $1.30BRaised
Nov 5, 2026non-GAAP operating incomeFY2026$1.90B – $2.00BRaised
Nov 5, 2026Diluted ADS outstandingFY2026118Reaffirmed
Nov 5, 2026Other income (expense)FY2026$25.00M – $50.00MReaffirmed
Nov 5, 2026GAAP operating expensesFY2026$4.90B – $5.00BRaised
Nov 5, 2026Total revenueFY2026$6.90B – $7.00BRaised
Aug 5, 2026Diluted ADS outstandingFY2026118New
Aug 5, 2026Other income (expense)FY2026$25.00M – $50.00MNew
May 6, 2026GAAP operating incomeFY2026$750.00M – $850.00MNew
May 6, 2026Non-GAAP operating incomeFY2026$1.45B – $1.55BNew
May 6, 2026Diluted ADS outstandingFY2026118New
May 6, 2026Other income (expense)FY2026$25.00M – $50.00MNew
May 6, 2026GAAP operating expensesFY2026$4.70B – $4.90BNew
May 6, 2026Total revenueFY2026$6.30B – $6.50BNew
Feb 26, 2026GAAP operating incomeFY2026$700.00M – $800.00MNew
Feb 26, 2026Non-GAAP operating incomeFY2026$1.40B – $1.50BNew
Feb 26, 2026GAAP operating expenses (combined R&D and SG&A)FY2026$4.70B – $4.90BNew
Feb 26, 2026Total revenueFY2026$6.20B – $6.40BNew
Nov 6, 2025total revenueFY2025$5.10B – $5.30BNew
Aug 6, 2025GAAP Operating Expenses (R&D and SG&A)FY2025$4.10B – $4.40BNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Adjusted figures

Non-GAAP numbers BeOne Medicines reports itself, taken from its earnings releases

MeasureQ3 FY2026Q2 FY2026Q1 FY2026FY2026Q4 FY2025FY2025
Adjusted income from operations$612.23M$503.03M$414.39M$1.90B––
Adjusted net income$538.74M$444.50M$375.04M–$224.98M$917.60M
Adjusted diluted Earnings per ADS$4.59$3.84$3.24–$1.95$8.09
Free Cash Flow$473.53M$435.34M$160.55M–$379.83M$941.74M

Read from the company's own earnings releases; hover a figure for the sentence it came from. Companies choose what to leave out of an adjusted number and there is no standard for it, so these are not comparable between companies the way the audited statements are. Margins here are computed from the adjusted revenue of the same period.

Press releases

Releases BeOne Medicines filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. News
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Update
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?